FDA Advisory Committee Vote Boosts Galleri Prospects Amid Solid Volume Growth

What happened

GRAIL reported Q3 2026 financial results with Galleri test volume up ~24% year-over-year to more than 56,000 tests, and year-to-date volume up 36% to more than 174,000. Galleri revenue grew 14% year-over-year to $37.3 million, but the slower revenue growth relative to volume indicates continued average selling price pressure. The FDA Advisory Committee voted in favor of approval of Galleri, a significant regulatory milestone that had been a key watch item in our prior analysis. However, this is an advisory vote, not final FDA approval, and the FDA's decision and subsequent reimbursement policies remain uncertain. The company continues to operate at a significant loss, and despite improving cash burn trends, the path to profitability hinges on securing broad adoption and payer coverage following potential approval.

Implication

The advisory committee's favorable vote increases the probability of FDA approval for Galleri, which could unlock Medicare and commercial coverage and accelerate adoption. However, FDA approval is not guaranteed, and even if granted, the timeline for reimbursement decisions and real-world evidence requirements could delay revenue inflection. Galleri volume growth remains robust, but the 14% revenue growth versus 24% volume growth confirms ongoing ASP erosion, which may continue as the company seeks broader access. GRAIL's cash burn is improving, but the company still faces significant losses and will require substantial capital to support commercialization if approval occurs. Therefore, while the news is encouraging, we maintain a HOLD rating and recommend monitoring final FDA action, reimbursement developments, and volume/ASP trends before committing new capital.

Thesis delta

Our prior HOLD thesis highlighted PMA approval and reimbursement as key binary catalysts. The FDA Advisory Committee vote in favor of Galleri approval materially de-risks the regulatory pathway, shifting the probability of success upward. However, final FDA action and payer reimbursement remain uncertain, and we will not upgrade to BUY until these milestones are achieved; we may upgrade if the FDA grants approval, but could downgrade if approval is delayed or denied.